Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143635 · ClinicalTrials.gov registry record · Phase 1
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
NCT02143635 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 208 participants.
The verdict
NCT02143635, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
Study Summary
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
Interventions
- DRUG HDM201
- DRUG ancillary treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2014-07-07 |
| Est. Completion | 2020-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143635
The ClinicalTrials.gov registry entry for NCT02143635 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HDM201 is the first listed.
NCT02143635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02143635 about?
NCT02143635 is a clinical study titled "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt". To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
What is the current status of trial NCT02143635?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2014-07-07. Estimated completion is 2020-06-09.
What interventions are being tested in trial NCT02143635?
The interventions under investigation include: HDM201 (DRUG), ancillary treatment (DRUG).
Who is sponsoring clinical trial NCT02143635?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.